EGFR and pancreatic neoplasm: Encouraging findings have also been reported with the combination of gemcitabine and the anti-EGFR chimeric monoclonal antibody cetuximab in the first-line treatment of patients with advanced pancreatic cancer (Xiong et al, 2004).